By phenotypic screening, these authors have identified small molecules, that protected podocytes against injury in vitro. This  findings identify pyrintegrin as a potential therapeutic candidate and show the use of podocyte-based screening assays for identifying novel therapeutics for proteinuric kidney diseases.

To know more of this article, follow this link : http://www.ncbi.nlm.nih.gov/pubmed/25858967